DMT410
Primary Axillary Hyperhidrosis
Key Facts
About Dermata Therapeutics
Dermata Therapeutics is a clinical-stage biotech company focused on developing novel therapies for medical and aesthetic skin conditions through its proprietary Spongilla technology platform. Its lead candidate, DMT310, has completed Phase 2b trials for moderate-to-severe acne and rosacea, demonstrating a unique dual mechanism of physical exfoliation and anti-inflammatory bioactivity. The company's strategy is to advance its pipeline through clinical milestones to secure regulatory approval and partnership opportunities, operating as a lean, publicly-traded entity in a high-value dermatology market. Its micro-cap status reflects the binary, milestone-driven nature of its development stage.
View full company profileAbout Dermata Therapeutics
Dermata Therapeutics is a clinical-stage biotech company focused on developing novel therapies for medical and aesthetic skin conditions through its proprietary Spongilla technology platform. Its lead candidate, DMT310, has completed Phase 2b trials for moderate-to-severe acne and rosacea, demonstrating a unique dual mechanism of physical exfoliation and anti-inflammatory bioactivity. The company's strategy is to advance its pipeline through clinical milestones to secure regulatory approval and partnership opportunities, operating as a lean, publicly-traded entity in a high-value dermatology market. Its micro-cap status reflects the binary, milestone-driven nature of its development stage.
View full company profileAbout Dermata Therapeutics
Dermata Therapeutics is a clinical-stage biotech company focused on developing novel therapies for medical and aesthetic skin conditions through its proprietary Spongilla technology platform. Its lead candidate, DMT310, has completed Phase 2b trials for moderate-to-severe acne and rosacea, demonstrating a unique dual mechanism of physical exfoliation and anti-inflammatory bioactivity. The company's strategy is to advance its pipeline through clinical milestones to secure regulatory approval and partnership opportunities, operating as a lean, publicly-traded entity in a high-value dermatology market. Its micro-cap status reflects the binary, milestone-driven nature of its development stage.
View full company profileTherapeutic Areas
Other Primary Axillary Hyperhidrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Sofdra™ (sofpironium) topical gel, 12.45% | Botanix Pharmaceuticals | Approved |
| Qbrexza® | Fortress Biotech | Marketed |